The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Fruits
I see the more articulate version of you is posting on your account today...
You are obviously not doing a very good job, so they have to feed you
text! Saying that, it really is ridiculous to think we should use timelines
from 10 years ago to guide our current expectations.. Just an excuse for
a total lack of progress/updates. If we have not started a trial by the AGM
they will have to come up with something better than deals take a long time!
It seems RM & Co. never get a deal.... They over promise and under deliver.
RM said negtiations were ongoing after ACTIV2 to find a suitable trial..Nothing.
We were repeatedly told after SPRINTER deep dive there was a lot of interest
and they were throwing arrows/darts... Nothing! All we have is participation
in UNIVERSAL which is not even using our drug..... What a track record.. !! But
hey RM you awarded yourself a 100% bonus out of the placing funds, so if you do
come back looking for more funds, start by paying that back !!!
To be fair..
It is reasonable to wonder why SNG has not had a Partnership deal since 2014..
RM & Co sold us the story that SPRINTER results warranted further analysis..They touted our data around
every Conference in the sector but did not get any interest. After Activ2 was halted we were told
we were in discussions to look for an alternative trial..Nothing happened. I have a little experience
of following cancer drugs that show results but NICE turn down as not economically viable. My
concern here is that we seem very much adrift after 20 years listed and longer as a research outfit.
There is an unmet need for a broad spectrum anti viral, so you have to wonder why we are trying
to fund a trail and no BP has offered to Partner on a reasonable deal? Are we looking too niche
targeting the elderly who are seriously ill.... I think the answer is not far off... If we do not have
enough funds to complete our planned P2's then RM should be able to attract a JV/Partner
if the sector believes we have the potential to be commercial.. IF we do not have enough funds
and we have to get a financing deal/placing then I think the sector are not convinced....
Most here do not want to discuss this view, fair enough, just my thoughts as we wait for news!
Doc.Dan
We will only get a Partner if they get a large slice of the pie..
I guess TGF will have to be onboard whatever goes down...But
I know Tommy insists a Summer Trial is not an issue, but a Partner
may well want to wait for later in the year. I still think RM could
announce they want the UNIVERSAL results to define the design...!
There has never been an official announcement they are using the first 300
patients results, that was just another sweetner from RM at the AGM
to pacify disappointed shareholders IMHO!
Doc.Dan
Last year was 27th April not 17th which was notice of the results.
How ridiculous to say I will enjoy news our cash reserves are dwindling.. !!!
SNG have said they have enough, but I just do not think our reserves are sufficient,
but would be very pleased to be wrong, it makes a big difference to our investment.
I disagree it is better to get a BP on board before results, what bargaining power would
we have to negotiate a good deal... We need results first and a small placing would be a better option!
Mind you as long as RM is getting paid I doubt he cares, he can always grant himself more options!
Dunk
That is a fair question, I don't know the answer.
But Tommy monitors this board daily and challenges every
post that criticises RM/SNG. He has never posted on any other stock,
and posts comments like "managing our expectations" that is
not the terminology of a genuine PI discussing their investment!
I have posted a few times later in the evening or at weekends
just to test how long it takes Tommy to respond and it is always
within 10/15 mins.... As you can see for yourself if I post during
trading hours Tommy is instantly on here to dispute everything
I post.. He tells everyone to be patient, but is the most manic poster
on this board.... Hence I think this is not the behaviour of a PI
in SNG.... There is an alternative agenda IMHO!
Tommy
"Another day of mainly irrelevant nonsense"
That certainly applies to your posts today.... Claiming to know
anything more than any other poster is nonsense... I think you too
are a paid poster, here to cheer on RM, attacking any post
that criticses SNG.. I am sure claiming to have insider info is against the rules
so I am going to report you....!
Fruits...
I think more than one person posts under your account....
Some of your posts are quite immature and abusive with
limited use of vocabulary, against a view on this topic
that seems a stark contrast to your usual dross ! IMHO!
Tommy... You have sunk to a new low!
One of the worst things posters do is to pretend thet have inside info.
The results RNS is likey out at the end of April like last year so long
after the new financial year...
"The Market will be able to judge the potential for our our drug. "
The market does not have a crystal ball Tommy, we need to pass
P2's conclusively before the market will take a view. Furthermore,
SNG will need to demonstrate their financial position is robust
enough to comfortably complete the planned programme. RM
has damaged investor confidence, so buyers will need a reason
beyond just starting P2's to invest here. The key thing now is
the results RNS and the assurance that we are on track with
adequate funds.... SNG need to deliver on promises...
Trinity
You seem to be obsessed with me...
If you are going to quote a post from me, then be mature enough to post
the whole post and not a snippet that supports your paranoia !
Here is what I posted on 8th Feb...
I think we will be fine even if we slip into H2... TGF have too much to lose
by not making sure the P2's go ahead... The new CFO will be looking at least
12 months ahead at all times... They have options, cut staff, financing, small placing..
A delay would be disappointing but not the end IMHO!
Totally consistent with my posts of late, I see a Placing coming, it will
give us the chance to complete the P2's..... What is your problem??
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that it has received a requisition from shareholders representing over 7% of the Company's voting rights to convene a General Meeting ("GM") of the Company (the "Requisition") under section 303 of the Companies Act 2006 (the "Act"). The Requisition requests for the following Ordinary Resolutions to be proposed at the General Meeting:
1. That Martin Lampshire be removed from the board of directors of the Company with immediate effect.
2. That Kevin Cox be removed from the board of directors of the Company with immediate effect.
3. That Adrian De Courcey be appointed as a non-executive director of the Company with immediate effect.
4. That Benjamin Snipe be appointed as a non-executive director of the Company with immediate effect.
5. That Ray Horn be appointed as Board Observer of the Company with immediate effect.
6. That, subject to the passing of resolution 2, a) an interim Chairperson be appointed to the Board of the Company; and b) Shard Capital, the Company's broker, be requested by the Board to provide at least one candidate for the permanent role of non-executive Chairperson by 31 May 2024; if at least one candidate is provided to the Board, the Board may decide to appoint to the role accordingly, but is not required to; otherwise the Board is to proceed with recruitment to the role using services of an external recruitment agency.
7. That any person appointed as a director of the Company since the date of the requisition of the general meeting of the Company at which this resolution is proposed, and who is not one of the persons referred to in the resolutions numbered 3 and 4 above, be and is hereby removed as a director of the Company.
A further announcement will be made by the Company relating to the calling of a General Meeting and a Notice of General Meeting and accompanying circular will posted to shareholders.
Pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition was received, and this meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
IMHO
I can see RM saying they need to wait for the UNIVERSAL results before
completing their design for our P2's That way he can cover up a delay by
looking to be meticulous in the planning phase, and then saying the delay
was prudent and they need more funds.. We only have an AGM report
that they were using the results of the first 300 Patients, that was never
released officially in a RNS... It would be difficult for TGF to reject a raise
under such circumstances.....
Well Tommy
It's only been 2 years..... Sometimes on AIM you get taken for a ride...!
I am sure RM apprecitaes lots of patience, it means he can carry on draining
our cash reserves with £350K a year for delivering nothing.. I wish AIM
was more like football, if you are the manager and do not deliver you are sacked in months
not allowed to hide on the Solent in your yacht, ignoring those who pay your wages..
His arrogance knows no bounds....But Tommy comes a close second!
Tommy, " We’re very close to an RNS " Don't post nonsense, 4 months left in H1
2 Months left to results.... So back up your post with some substance or admit
you don't have a clue when news will land like the rest of us! Doh.....
Aether, it was not considered the end, RM confirmed discussions were ongoing but
clearly came to nothing... Exactly as I said in my post.. Try and keep up! From the RNS..
The development today is due to the significant shift in the nature of the pandemic which would necessitate a substantial modification of the study design not feasible in this multiple treatment-arm, platform trial.
Due to these changes in the pandemic, a new clinical trial design is needed to evaluate the efficacy of SNG001 against COVID-19. As a result, lead investigators from ACTIV-2 and Synairgen are in ongoing discussions to try to identify an appropriate clinical trial to continue the evaluation of SNG001.
Doc.Dan
Re: US..... In light of the fact we never benefitted from Activ 2 with no explanation
of why we were moth balled, then I do not see any reason why our P2's trialing in
the US makes any difference... It will be expensive and all that really matters is
that they return a conclusive result... Saying that I wonder if RM & Co, did not have
the skills to negotiate a way of progressing to a P3, I am really surprised it hardly
ever gets a mention on here, but RM said they were talking constantly at the 2022 AGM
so we deserve to know why nothing came from it... I do not remember if it was discussed
at the 2023 AGM ??
Spacman
You seem to think a Corporate event is a solution with no downside, but
it would mean giving away a slice of the pie... IMHO it would be a real shame
to do that before P2 results...Yes, a placing at this level is not great news, but
at least we still own everything. TFG will allow it if needed, they really do not have
much choice if we simply cannot complete the trials without further funding..
Anyway let's agree to disagree on this one, I think the results will define what
is going on and what happens next!